163 related articles for article (PubMed ID: 36510385)
1. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
Xiaozhe L; Meilan C; Beihui H; Junru L; Jingli G; Lifen K; Juan L
Integr Cancer Ther; 2022; 21():15347354221140402. PubMed ID: 36510385
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
3. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin.
Nara K; Taguchi A; Yamamoto T; Tsuruga T; Tojima Y; Miyamoto Y; Tanikawa M; Sone K; Mori M; Takada T; Suzuki H; Osuga Y
Support Care Cancer; 2023 Apr; 31(5):283. PubMed ID: 37074471
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T; Yoshimura A; Hayashi T; Kobayashi N; Saito K; Tsuneizumi M; Sawaki M; Hattori M; Nakada T; Yokota I; Iwata H
Breast Cancer; 2018 Nov; 25(6):729-735. PubMed ID: 29948956
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.
Braik T; Yim B; Evans AT; Kassem M; Mullane M; Lad T; Hussein L; Cleveland B; McDunn S
J Community Support Oncol; 2014 Feb; 12(2):65-70. PubMed ID: 24971407
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Jo SJ; Shin H; Jo S; Kwon O; Myung SK
Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
11. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Lian S; Zhang X; Zhang Y; Zhao Q
Clin Exp Dermatol; 2021 Jun; 46(4):629-635. PubMed ID: 33190278
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
14. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
15. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
Hu X; Dong M; Liang X; Liu Z; Li Q
Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
[TBL] [Abstract][Full Text] [Related]
16. Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients.
Zheng YF; Fu X; Wang XX; Sun XJ; He XD
World J Clin Cases; 2021 Nov; 9(33):10075-10087. PubMed ID: 34904077
[TBL] [Abstract][Full Text] [Related]
17. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
Zhao Y; Su W; Liang G; Shan X; Ma W; Tang D; Li L; Niu X; Zhao S; Zhang Q; Zhao W
BMC Pharmacol Toxicol; 2021 Oct; 22(1):63. PubMed ID: 34696815
[TBL] [Abstract][Full Text] [Related]
18. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
Chen M; Zhang L; Wang Q; Shen J
PLoS One; 2013; 8(8):e72245. PubMed ID: 23977264
[TBL] [Abstract][Full Text] [Related]
19. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
20. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]